Vyvgart (efgartigimod alfa)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Vyvgart (efgartigimod alfa), covering 2025-03-13 to 2026-01-22. Get the full timeline:
Most recent: Clinical Trial Update: Evaluating the Long-Term Safety and Tolerability of Efgartigimod PH20 SC Administered Subcutaneously in Patients With Generalized Myasthenia Gravis [Phase 3]